Nationwide Children's Hospital' Infant Corticosteroid Clinical Trial for Duchenne muscular dystrophy
Actively RecruitingPhase 4Reducing Inflammation
Study Overview
- Age
- 0–3 years
- Phase
- Phase 4
- Sponsor
- Nationwide Children's Hospital
- Therapeutic Approach
- Reducing Inflammation
- Variant Requirement
- Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype.
- Eligible Sex
- Male
- Ambulation
- Ambulatory
- Study Start (Actual)
- 2021-04-30
- Primary Completion (Estimated)
- 2026-08
- Study Completion (Estimated)
- 2026-12
- Enrollment (Estimated)
- 26
- Countries
- United States
Study Requirements and Criteria
Inclusion Criteria
- Subjects ages 1 month through 30 months
- Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.
Exclusion Criteria
Prior treatment with Glucocorticosteroids
Contact Information
This section provides contact details for people who can answer questions about joining this study
- Name: Sara Marshall
- Phone Number: 614-355-3508
- Email: [email protected]
Clinical Trial Registry
NCT ID
NCT05412394This information is provided for educational purposes only. Always consult the study investigators before making medical decisions.